The DOI matches its Crossref record; 239 of the 239 references it cites were found in a registry or an index.
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605 · cited 2×
“Importantly, in combination with transforming growth factor-β (TGF-β), IL-6 promotes the differentiation of Th17 cells by activating transcription factors including retinoic acid-related orphan receptor RORγt and RORα (Veldhoen et al., 2006).”
BackgroundMechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
Haine, M. M.-L., & Meeùs, N. (1986) · Cited by 3,464
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 3×
“In contrast to IL-6R, gp130 is ubiquitously expressed and is also the signaling subunit of other cytokine members in the IL-6 family, including IL-11, IL-27, IL-31, cardiotrophin-1 (CTF1), cardiotrophin-like cytokine (CLC), ciliary neurotrophic factor (CNTF), oncostatin M, and leukemia inhibitory factor (LIF) (Heinric…”
BackgroundInterleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
IL‐6: Regulator of Treg/Th17 balance
Kimura, A., & Kishimoto, T. (2010) · European Journal of Immunology · doi:10.1002/eji.201040391 · Cited by 1,595
Smolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
BIRAC Consortium, Stahl, E. A., YEAR Consortium, Raychaudhuri, S., Remmers, E. F., Xie, G., Eyre, S., Thomson, B. P., Li, Y., Kurreeman, F. A. S., et al. (2010) · Nature Genetics · doi:10.1038/ng.582 · Cited by 1,253
Jego, G., Palucka, A. K., Blanck, J.-P., Chalouni, C., Pascual, V., & Banchereau, J. (2003) · Immunity · doi:10.1016/s1074-7613(03)00208-5 · Cited by 1,067
New therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928 · cited 1×
“Both human and viral IL-6 can contribute to the pathogenesis of virus-infected Castleman disease (Yoshizaki et al., 1989; Aoki et al., 2001).”
BackgroundPrediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes
Lossos, I. S., Czerwinski, D. K., Alizadeh, A. A., Wechser, M. A., Tibshirani, R., Botstein, D., & Levy, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032520 · Cited by 911
The two faces of IL-6 on Th1/Th2 differentiation
Diehl, S., & Rincón, M. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00210-9 · Cited by 872
Agustí, A., Edwards, L. D., Rennard, S. I., MacNee, W., Tal-Singer, R., Miller, B. E., Vestbo, J., Lomas, D. A., Calverley, P. M. A., Wouters, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037483 · Cited by 848
IL-6: From its discovery to clinical applications
Kishimoto, T. (2010) · International Immunology · doi:10.1093/intimm/dxq030 · Cited by 846
Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomšič, M., Alecock, E., Woodworth, T., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105197 · Cited by 797
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Umebayashi, H., Murata, T., Miyoshi, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60454-7 · Cited by 789
Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32533 · Cited by 779
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730 · cited 1×
“During acute inflammation, monocytes and macrophages are the main producers of IL-6 after activation of Toll-like receptors (TLRs) via a MyD88-dependent pathway, whereas T cells appear to be the major source of IL-6 during chronic inflammation (Naugler & Karin, 2008).”
BackgroundGabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60250-0 · Cited by 672
Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666
Interleukin-6 and its receptor: a paradigm for cytokines
Kishimoto, T., Akira, S., & Taga, T. (1992) · Science · doi:10.1126/science.1411569 · Cited by 665
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
Barr, T. A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., Fan, B., O’Connor, R. A., Anderton, S. M., Bar-Or, A., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111675 · Cited by 649
Rose-John, S., Scheller, J., Elson, G., & Jones, S. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105674 · Cited by 647
Hexameric Structure and Assembly of the Interleukin-6/IL-6 α-Receptor/gp130 Complex
Boulanger, M. J., Chow, D.-C., Brevnova, E. E., & Garcia, K. C. (2003) · Science · doi:10.1126/science.1083901 · Cited by 642
Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., & Rose‐John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 641
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Myeloid-derived suppressor cell heterogeneity and subset definition
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., & Bronte, V. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.021 · Cited by 630
Role of IL-6 in Asthma and Other Inflammatory Pulmonary Diseases
Rincon, M., & Irvin, C. G. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4874 · Cited by 621
Interleukin 6 is required for the development of collagen-induced arthritis
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, F., Poli, V., & Ciliberto, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.461 · Cited by 604
Interleukin-6: discovery of a pleiotropic cytokine.
Kishimoto, T. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1916 · Cited by 596
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
Neurath, M. F., & Finotto, S. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.02.003 · Cited by 576
Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 566
Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis
Linker-Israeli, M., Deans, R. J., Wallace, D. J., Prehn, J., Ozeri-Chen, T., & Klinenberg, J. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.1.117 · Cited by 549
Korkaya, H., Kim, G.-I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 538
Illei, G. G., Shirota, Y., Yarboro, C. H., Daruwalla, J., Tackey, E., Takada, K., Fleisher, T., Balow, J. E., & Lipsky, P. E. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27221 · Cited by 507
Trikha, M., Corringham, R. E., Klein, B., & Rossi, J. (2003) · PubMed · Cited by 506
Palmqvist, P., Persson, E., Conaway, H. H., & Lerner, U. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.6.3353 · Cited by 486
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., Kishimoto, T., & Yoshizaki, K. (2000) · Blood · doi:10.1182/blood.v95.1.56 · Cited by 441
Dienz, O., Eaton, S. M., Bond, J. P., Neveu, W., Moquin, D., Noubade, R., Briso, E. M., Charland, C., Leonard, W. J., Ciliberto, G., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081571 · Cited by 439
Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer
Salgado, R., Junius, S., Benoy, I., Van Dam, P., Vermeulen, P., Van Marck, E., Huget, P., & Dirix, L. Y. (2003) · International Journal of Cancer · doi:10.1002/ijc.10833 · Cited by 435
Celli, B. R., Locantore, N., Yates, J., Tal-Singer, R., Miller, B. E., Bakke, P., Calverley, P., Coxson, H., Crim, C., Edwards, L. D., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1792oc · Cited by 432
Derenne, S., Monia, B., Dean, N. M., Taylor, J. K., Rapp, M.-J., Harousseau, J.-L., Bataille, R., & Amiot, M. (2002) · Blood · doi:10.1182/blood.v100.1.194 · Cited by 427
IL-6 is required for the development of Th1 cell-mediated murine colitis
Yamamoto, M., Yoshizaki, K., Kishimoto, T., & Ito, H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4878 · Cited by 411
Kremer, J. M., Blanco, R., Brzosko, M., Burgos-Vargas, R., Halland, A.-M., Vernon, E., Ambs, P., & Fleischmann, R. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30158 · Cited by 409
Hartman, Z. C., Poage, G. M., den Hollander, P., Tsimelzon, A., Hill, J., Panupinthu, N., Zhang, Y., Mazumdar, A., Hilsenbeck, S. G., Mills, G. B., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4524-t · Cited by 409
IL-6 Regulates Neutrophil Trafficking during Acute Inflammation via STAT3
Fielding, C. A., McLoughlin, R. M., McLeod, L., Colmont, C. S., Najdovska, M., Grail, D., Ernst, M., Jones, S. A., Topley, N., & Jenkins, B. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2189 · Cited by 408
Inhibition of Th1 Differentiation by IL-6 Is Mediated by SOCS1
Diehl, S., Anguita, J., Hoffmeyer, A., Zapton, T., Ihle, J. N., Fikrig, E., & Rincón, M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00078-9 · Cited by 399
Nakahara, H., Song, J., Sugimoto, M., Hagihara, K., Kishimoto, T., Yoshizaki, K., & Nishimoto, N. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11143 · Cited by 395
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 390
Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389
Identification of IL6R and chromosome 11q13.5 as risk loci for asthma
Ferreira, M. A., Matheson, M. C., Duffy, D. L., Marks, G. B., Hui, J., Le Souëf, P., Danoy, P., Baltic, S., Nyholt, D. R., Jenkins, M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60874-x · Cited by 381
Interleukin-6 in bone metastasis and cancer progression
Ara, T., & DeClerck, Y. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.026 · Cited by 379
Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics
Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370
Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?
Grivennikov, S., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.020 · Cited by 368
Serum interleukin‐6 levels reflect the disease status of colorectal cancer
Chung, Y., & Chang, Y. (2003) · Journal of Surgical Oncology · doi:10.1002/jso.10269 · Cited by 353
Oestrogen receptor negative breast cancers exhibit high cytokine content
Chavey, C., Bibeau, F., Gourgou-Bourgade, S., Burlinchon, S., Boissière, F., Laune, D., Roques, S., & Lazennec, G. (2007) · Breast Cancer Research · doi:10.1186/bcr1648 · Cited by 349
Serada, S., Fujimoto, M., Mihara, M., Koike, N., Ohsugi, Y., Nomura, S., Yoshida, H., Nishikawa, T., Terabe, F., Ohkawara, T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802218105 · Cited by 349
Interleukin-6, Secreted by Human Ovarian Carcinoma Cells, Is a Potent Proangiogenic Cytokine
Nilsson, M. B., Langley, R. R., & Fidler, I. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0623 · Cited by 349
Samson, M., Audia, S., Janikashvili, N., Ciudad, M., Trad, M., Fraszczak, J., Ornetti, P., Maillefert, J., Miossec, P., & Bonnotte, B. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34477 · Cited by 347
Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G., Taga, T., & Kishimoto, T. (1993) · Blood · doi:10.1182/blood.v82.4.1120.1120 · Cited by 343
Li, Y., de Haar, C., Chen, M., Deuring, J., Gerrits, M. M., Smits, R., Xia, B., Kuipers, E. J., & van der Woude, C. J. (2010) · Gut · doi:10.1136/gut.2009.184176 · Cited by 339
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.
Conze, D. B., Weiss, L., Regen, P. S., Bhushan, A., Weaver, D. L., Johnson, P. F., & Rincón, M. (2001) · PubMed · Cited by 334
Interleukin-6 Is an Autocrine Growth Factor in Human Prostate Cancer
Giri, D., Ozen, M., & Ittmann, M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63067-2 · Cited by 334
Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis
Maimone, D., Gregory, S., Arnason, B. G. W., & Reder, A. T. (1991) · Journal of Neuroimmunology · doi:10.1016/0165-5728(91)90073-g · Cited by 333
Chalaris, A., Rabe, B., Paliga, K., Lange, H., Laskay, T., Fielding, C. A., Jones, S. A., Rose-John, S., & Scheller, J. (2007) · Blood · doi:10.1182/blood-2007-01-067918 · Cited by 329
Mihara, M., Kasutani, K., Okazaki, M., Nakamura, A., Kawai, S., Sugimoto, M., Matsumoto, Y., & Ohsugi, Y. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.05.010 · Cited by 328
Interleukin-6: from an inflammatory marker to a target for inflammatory diseases
Rincon, M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.003 · Cited by 328
Involvement of IL–6 in the pathogenesis of inflammatory bowel disease and colon cancer
Atreya, R., & Neurath, M. F. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:3:187 · Cited by 324 · cited 7×
“128 6 7 9 31 34 35 35 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12835 ronic obstructive pulmonary disease; CRC, colorectal cancer; CRP, C-reactive protein; CSC, cancer stem cells; DLT, dose-limiting R, epidermal growth factor receptor; IBD, inflammator…”
BackgroundInfluentialDuncan, M. R., & Berman, B. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12483971 · Cited by 323
Cytokines in pancreatic carcinoma: Correlation with phenotypic characteristics and prognosis
Ebrahimi, B., Tucker, S. L., Li, D., Abbruzzese, J. L., & Kurzrock, R. (2004) · Cancer · doi:10.1002/cncr.20672 · Cited by 315
Choi, Y. S., Eto, D., Yang, J. A., Lao, C., & Crotty, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203032 · Cited by 307
Kim, S.-Y., Kang, J. W., Song, X., Kim, B. K., Yoo, Y. D., Kwon, Y. T., & Lee, Y. J. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.01.007 · Cited by 297
Serum interleukin-6 levels in colorectal cancer patients—a summary of published results
Knüpfer, H., & Preiss, R. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-009-0818-8 · Cited by 291
Fayad, L., Keating, M. J., Reuben, J. M., O'Brien, S., Lee, B.-N., Lerner, S., & Kurzrock, R. (2001) · Blood · doi:10.1182/blood.v97.1.256 · Cited by 290
Dougados, M., Kissel, K., Sheeran, T., Tak, P. P., Conaghan, P. G., Mola, E. M., Schett, G., Amital, H., Navarro-Sarabia, F., Hou, A., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201282 · Cited by 287
Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation
Chen, Z., Laurence, A., & O'Shea, J. J. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2007.10.015 · Cited by 274
Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
Sato, K., Tsuchiya, M., Saldanha, J. W., Koishihara, Y., Ohsugi, Y., Kishimoto, T., & Bendig, M. M. (1993) · PubMed · Cited by 274
Hirohata, S., & Miyamoto, T. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330506 · Cited by 273
Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis
Takagi, N., Mihara, M., Moriya, Y., Nishimoto, N., Yoshizaki, K., Kishimoto, T., Takeda, Y., & Ohsugi, Y. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2117::aid-art6>3.0.co;2-p · Cited by 270
Interleukin-6 regulation of prostate cancer cell growth.
Culig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20477 · Cited by 269
The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site.
Müllberg, J., Oberthür, W., Lottspeich, F., Mehl, E., Dittrich, E., Graeve, L., Heinrich, P. C., & Rose-John, S. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.10.4958 · Cited by 269
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
Bataille, R., Barlogie, B., Lu, Z., Rossi, J., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., & Klein, B. (1995) · Blood · doi:10.1182/blood.v86.2.685.bloodjournal862685 · Cited by 269
Blay, J.-Y., Rossi, J.-F., Wijdenes, J., Menetrier-Caux, C., Schemann, S., Négrier, S., Philip, T., & Favrot, M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970729)72:3<424::aid-ijc9>3.0.co;2-r · Cited by 261
Ruiz-Irastorza, G., Khamashta, M. A., Castellino, G., & Hughes, G. R. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04239-2 · Cited by 257
Review: IL-6 Transsignaling: The In Vivo Consequences
Jones, S. A., Richards, P. J., Scheller, J., & Rose-John, S. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.241 · Cited by 251
Circulating interleukin-6 levels in patients with bronchial asthma.
Yokoyama, A., Kohno, N., Fujino, S., Hamada, H., Inoue, Y., Fujioka, S., Ishida, S., & Hiwada, K. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.5.7735584 · Cited by 248
Duan, Z., Foster, R., Bell, D. A., Mahoney, J., Wolak, K., Vaidya, A., Hampel, C., Lee, H., & Seiden, M. V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0861 · Cited by 247
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
Bayliss, T. J., Smith, J. T., Schuster, M., Dragnev, K. H., & Rigas, J. R. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.627850 · Cited by 243
Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease
van Rhee, F., Fayad, L., Voorhees, P., Furman, R., Lonial, S., Borghaei, H., Sokol, L., Crawford, J., Cornfeld, M., Qi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2377 · Cited by 243
IL-6-regulated transcription factors
Akira, S. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(97)00063-0 · Cited by 233
Lauta, V. M. (2003) · Cancer · doi:10.1002/cncr.11072 · Cited by 232
Glucocorticoids inhibit the production of IL 6 from monocytes, endothelial cells and fibroblasts
Waage, A., Slupphaug, G., & Shalaby, R. (1990) · European Journal of Immunology · doi:10.1002/eji.1830201112 · Cited by 231
Watson, J. M., Sensintaffar, J., Berek, J. S., & Martı́nez-Maza, O. (1990) · PubMed · Cited by 221
Dorff, T. B., Goldman, B., Pinski, J. K., Mack, P. C., Lara, P. N., Van Veldhuizen, P. J., Quinn, D. I., Vogelzang, N. J., Thompson, I. M., & Hussain, M. H. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3122 · Cited by 212
Bellone, G., Smirne, C., Mauri, F. A., Tonel, E., Carbone, A., Buffolino, A., Dughera, L., Robecchi, A., Pirisi, M., & Emanuelli, G. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0047-0 · Cited by 209
Sanchez-Correa, B., Bergua, J. M., Campos, C., Gayoso, I., Arcos, M. J., Bañas, H., Morgado, S., Casado, J. G., Solana, R., & Tarazona, R. (2013) · Cytokine · doi:10.1016/j.cyto.2012.12.023 · Cited by 208
C-reactive protein in rheumatology: biology and genetics
Rhodes, B., Fürnrohr, B. G., & Vyse, T. J. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.37 · Cited by 207
Kurzrock, R., Voorhees, P. M., Casper, C., Furman, R. R., Fayad, L., Lonial, S., Borghaei, H., Jagannath, S., Sokol, L., Usmani, S. Z., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3349 · Cited by 205
Eghtedar, A., Verstovsek, S., Estrov, Z., Burger, J., Cortes, J., Bivins, C., Faderl, S., Ferrajoli, A., Borthakur, G., George, S., et al. (2012) · Blood · doi:10.1182/blood-2011-12-400051 · Cited by 200
Meng, F., Henson, R., Wehbe-Janek, H., Smith, H., Ueno, Y., & Patel, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607712200 · Cited by 200
Loeffler, S., Fayard, B., Weis, J., & Weissenberger, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.20871 · Cited by 200
Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., Qi, M., Bandekar, R., Vermeulen, J. T., Cornfeld, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.014 · Cited by 197
Shima, Y., Kuwahara, Y., Murota, H., Kitaba, S., Kawai, M., Hirano, T., Arimitsu, J., Narazaki, M., Hagihara, K., Ogata, A., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/keq275 · Cited by 195
Liang, B., Gardner, D. B., Griswold, D. E., Bugelski, P. J., & Song, X. Y. R. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02433.x · Cited by 190
Serum Interleukin 6, Plasma VEGF, Serum VEGF, and VEGF Platelet Load in Breast Cancer Patients
Benoy, I., Salgado, R., Colpaert, C., Weytjens, R., Vermeulen, P. B., & Dirix, L. Y. (2002) · Clinical Breast Cancer · doi:10.3816/cbc.2002.n.008 · Cited by 188
The relationship between weight loss and interleukin 6 in non-small-cell lung cancer
Scott, H., McMillan, D., Crilly, A., McArdle, C., & Milroy, R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.294 · Cited by 183
Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma
Yoshida, N., Ikemoto, S., Narita, K., Sugimura, K., Wada, S., Yasumoto, R., Kishimoto, T., & Nakatani, T. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600257 · Cited by 182
Song, L., Rawal, B., Nemeth, J. A., & Haura, E. B. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0502 · Cited by 177
Negrier, S., Perol, D., Menetrier-Caux, C., Escudier, B., Pallardy, M., Ravaud, A., Douillard, J.-Y., Chevreau, C., Lasset, C., & Blay, J.-Y. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.121 · Cited by 176
Rossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 166
Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells
Briso, E. M., Dienz, O., & Rincon, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7102 · Cited by 165
Hideshima, T., Chauhan, D., Hayashi, T., Akiyama, M., Mitsiades, N., Mitsiades, C., Podar, K., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207170 · Cited by 164
Burmester, G. R., Feist, E., Kellner, H., Braun, J., Iking-Konert, C., & Rubbert-Roth, A. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.139725 · Cited by 164
Shinriki, S., Jono, H., Ota, K., Ueda, M., Kudo, M., Ota, T., Oike, Y., Endo, M., Ibusuki, M., Hiraki, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0287 · Cited by 163
Cash, H., Relle, M., Weinmann‐Menke, J., Brochhausen, C., Jones, S. A., Topley, N., Galle, P. R., & Schwarting, A. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090194 · Cited by 161
IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice
Mihara, M., Takagi, N., Takeda, Y., & Ohsugi, Y. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00612.x · Cited by 159
Effect of Obesity on Clinical Presentation and Response to Treatment in Asthma
Dixon, A. E., Shade, D. M., Cohen, R. I., Skloot, G. S., Holbrook, J. T., Smith, L. J., Lima, J. J., Allayee, H., Irvin, C. G., & Wise, R. A. (2006) · Journal of Asthma · doi:10.1080/02770900600859123 · Cited by 158
Ashizawa, T., Okada, R., Suzuki, Y., Takagi, M., Yamazaki, T., Sumi, T., Aoki, T., Ohnuma, S., & Aoki, T. (2005) · Gastric Cancer · doi:10.1007/s10120-005-0315-x · Cited by 158
Schneider, A., Long, S. A., Cerosaletti, K. M., Ni, C., Samuels, P. L., Kita, M., & Buckner, J. H. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004970 · Cited by 158
Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Furuse, J., Inagaki, M., Higashi, S., Kato, H., Terao, K., & Ochiai, A. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.174 · Cited by 157
Cytokine gene polymorphisms and breast cancer susceptibility and prognosis*
Smith, K.-A., Bateman, A. C., Fussell, H., & Howell, W. M. (2004) · European Journal of Immunogenetics · doi:10.1111/j.1365-2370.2004.00462.x · Cited by 154
Gijbels, K., Damme, J. V., Proost, P., Put, W., Carton, H., & Billiau, A. (1990) · European Journal of Immunology · doi:10.1002/eji.1830200134 · Cited by 153
Anti‐interleukin‐6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases
Tanaka, T., Narazaki, M., & Kishimoto, T. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.023 · Cited by 153
Elevated Serum Interleukin-6 Levels in Patients with Pancreatic Cancer
Okada, S., Okusaka, T., Ishii, H., Kyogoku, A., Yoshimori, M., Kajimura, N., Yamaguchi, K., & Kakizoe, T. (1998) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/28.1.12 · Cited by 153
IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus
Chen, M., Chen, P.-T., Lu, M. S., Lin, P. Y., Chen, W., & Lee, K. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-26 · Cited by 151
Ataie-Kachoie, P., Pourgholami, M. H., & Morris, D. L. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.09.001 · Cited by 150
Voorhees, P. M., Manges, R., Sonneveld, P., Jagannath, S., Somlo, G., Krishnan, A. Y., Lentzsch, S., Frank, R. C., Zweegman, S., Wijermans, P., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12266 · Cited by 149
Wallner, L. P., Dai, J., Escara-Wilke, J. F., Zhang, J., Yao, Z., Lü, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., & Keller, E. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3447 · Cited by 148
IL-6 Is Required for Airway Mucus Production Induced by Inhaled Fungal Allergens
Neveu, W. A., Allard, J. B., Dienz, O., Wargo, M. J., Ciliberto, G., Whittaker, L. A., & Rincón, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802923 · Cited by 144
Bellone, G., Carbone, A., Smirne, C., Scirelli, T., Buffolino, A., Novarino, A., Stacchini, A., Bertetto, O., Palestro, G., Sorio, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3448 · Cited by 143
Interleukin-6 gene amplification and shortened survival in glioblastoma patients
Tchirkov, A., Khalil, T. A., Chautard, E., Mokhtari, K., Véronèse, L., Irthum, B., Vago, P., Kemeny, J., & Verrelle, P. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603586 · Cited by 140
McLoughlin, R. M., Hurst, S. M., Nowell, M. A., Harris, D. A., Horiuchi, S., Morgan, L. W., Wilkinson, T. S., Yamamoto, N., Topley, N., & Jones, S. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5676 · Cited by 140
Associations of IL6 polymorphisms with lung function decline and COPD
He, J., Foreman, M. G., Shumansky, K., Zhang, X., Akhabir, L., Sin, D. D., Man, S. F. P., DeMeo, D. L., Litonjua, A. A., Silverman, E. K., et al. (2009) · Thorax · doi:10.1136/thx.2008.111278 · Cited by 138
Flowers, L. O., Subramaniam, P. S., & Johnson, H. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208437 · Cited by 137
Yu, C.-C., Tsai, L., Wang, M., Yu, C.-H., Lo, W., Chang, Y.-C., Chiou, G., Chou, M., & Chiou, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3840 · Cited by 135
Possible Role for Tocilizumab, an Anti–Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia
Ando, K., Takahashi, F., Motojima, S., Nakashima, K., Kaneko, N., Hoshi, K., & Takahashi, K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2020 · Cited by 135
Katsume, A., Saito, H., Yamada, Y., Yorozu, K., Ueda, O., Akamatsu, K.-I., Nishimoto, N., Kishimoto, T., Yoshizaki, K., & Ohsugi, Y. (2002) · Cytokine · doi:10.1006/cyto.2002.2012 · Cited by 134
Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.
Desgeorges, A., Gabay, C., Silacci, P., Novick, D., Roux-Lombard, P., Grau, G. E., Dayer, J. M., VISCHER, T. L., & Guerne, P. A. (1997) · PubMed · Cited by 134
Shirota, Y., Yarboro, C. H., Fischer, R. T., Pham, T., Lipsky, P. E., & Illei, G. G. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201310 · Cited by 134
Critical Role of STAT3 in IL-6–Mediated Drug Resistance in Human Neuroblastoma
Ara, T., Nakata, R., Sheard, M. A., Shimada, H., Buettner, R., Groshen, S. G., Ji, L., Yu, H., Jove, R., Seeger, R. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2353 · Cited by 134
Diehl, S. A., Schmidlin, H., Nagasawa, M., Blom, B., & Spits, H. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.17 · Cited by 132
IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer
Chen, M., Lin, P., Wu, C., Chen, W., & Wu, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061901 · Cited by 132
Voorhees, P. M., Chen, Q., Kuhn, D. J., Small, G. W., Hunsucker, S. A., Strader, J. S., Corringham, R. E., Zaki, M. H., Nemeth, J. A., & Orlowski, R. Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1293 · Cited by 132
Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma
Kitaba, S., Murota, H., Terao, M., Azukizawa, H., Terabe, F., Shima, Y., Fujimoto, M., Tanaka, T., Naka, T., Kishimoto, T., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.013 · Cited by 131
IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma
Cozen, W., Gill, P. S., Ingles, S. A., Masood, R., nez-Maza, O. M. I., Cockburn, M., Gauderman, W. J., Pike, M. C., Bernstein, L., Nathwani, B. N., et al. (2004) · Blood · doi:10.1182/blood-2003-08-2860 · Cited by 131
Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y., & Yoshida, O. (1995) · PubMed · Cited by 127
Ravishankaran, P., & Karunanithi, R. (2011) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-9-18 · Cited by 125
Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease
Hosokawa, T., Kusugami, K., Ina, K., Ando, T., Shinoda, M., Imada, A., Ohsuga, M., Sakai, T., Matsuura, T., Ito, K., et al. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01989.x · Cited by 123
Santer, F. R., Malinowska, K., Čulig, Z., & Cavarretta, I. T. R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0200 · Cited by 120
A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Fulciniti, M., Hideshima, T., Vermot‐Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z., Patel, N., Smith, E., Wang, W., PRABHALA, R. H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1483 · Cited by 119
McKeown, D. J., Brown, D., Kelly, A. U., Wallace, A. M., & McMillan, D. C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602248 · Cited by 118
Miki, C., Konishi, N., Ojima, E., Hatada, T., Inoue, Y., & Kusunoki, M. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000034556.48527.6e · Cited by 118
Karkera, J. D., Steiner, H., Li, W., Skradski, V., Moser, P. L., Riethdorf, S., Reddy, M. P., Puchalski, T. A., Safer, K., Prabhakar, U., et al. (2011) · The Prostate · doi:10.1002/pros.21362 · Cited by 116
Alberti, C., Pinciroli, P., Valeri, B., Ferri, R., Ditto, A., Umezawa, K., Sensi, M., Canevari, S., & Tomassetti, A. (2011) · Oncogene · doi:10.1038/onc.2011.572 · Cited by 115
Interleukin 6 Is Associated with Cachexia in Patients with Prostate Cancer
Kuroda, K., Nakashima, J., Kanao, K., Kikuchi, E., Miyajima, A., Horiguchi, Y., Nakagawa, K., Oya, M., Ohigashi, T., & Murai, M. (2007) · Urology · doi:10.1016/j.urology.2006.09.039 · Cited by 115
IL-6-Like Cytokines and Cancer Cachexia: Consequences of Chronic Inflammation
Barton, B. E. (2001) · Immunologic Research · doi:10.1385/ir:23:1:41 · Cited by 110
A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis
Esparza-Gordillo, J., Schaarschmidt, H., Liang, L., Cookson, W., Bauerfeind, A., Lee-Kirsch, M.-A., Nemat, K., Henderson, J., Paternoster, L., Harper, J. I., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.01.057 · Cited by 107
Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer
Guo, Y., Nemeth, J. A., O'Brien, C. W., Susa, M., Liu, X., Zhang, Z., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1095 · Cited by 106
Cavarretta, I. T. R., Neuwirt, H., Untergasser, G., Moser, P. L., Zaki, M. H., Steiner, H., Rumpold, H. F., Fuchs, D., Hobisch, A., Nemeth, J. A., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210097 · Cited by 105
IL6 genotypes and colon and rectal cancer
Slattery, M. L., Wolff, R. K., Herrick, J. S., Caan, B. J., & Potter, J. D. (2007) · Cancer Causes & Control · doi:10.1007/s10552-007-9049-x · Cited by 103
The IL6R variation Asp358Ala is a potential modifier of lung function in subjects with asthma
Hawkins, G. A., Robinson, M., Hastie, A. T., Li, X., Li, H., Moore, W. C., Howard, T. D., Busse, W. W., ERZURUM, S. C., Wenzel, S. E., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.03.018 · Cited by 101
Xu, Z., Bouman‐Thio, E., Comisar, C. M., Frederick, B., van Hartingsveldt, B., Marini, J. C., Davis, H. M., & Zhou, H. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03964.x · Cited by 99
Mease, P. J., Strand, V., Shalamberidze, L., Dimić, A., Raskina, T. A., Xu, L., Liu, Y., & Smith, J. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200704 · Cited by 99
Keul, R., Heinrich, P. C., Müller-Newen, G., Muller, K., & Woo, P. (1998) · Cytokine · doi:10.1006/cyto.1997.0343 · Cited by 98
IL6 and CRPhaplotypes are associated with COPD risk and systemic inflammation: a case-control study
Yanbaeva, D. G., Dentener, M. A., Spruit, M. A., Houwing‐Duistermaat, J. J., Kotz, D., Passos, V. L., & Wouters, E. F. �. (2009) · BMC Medical Genetics · doi:10.1186/1471-2350-10-23 · Cited by 97
Interleukin-6, its role in fibrosing conditions
O’Reilly, S., Ciechomska, M., Cant, R., Hügle, T., & van Laar, J. M. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.04.003 · Cited by 96
Tsuboi, I., Tsuboi, I., Tanaka, H., Nakao, M., Shichijo, S., & Itoh, K. (1995) · Cytokine · doi:10.1006/cyto.1995.0047 · Cited by 95
Hoejberg, L., Bastholt, L., & Schmidt, H. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e3283543d72 · Cited by 95
Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.
Angelo, L. S., Talpaz, M., & Kurzrock, R. (2002) · PubMed · Cited by 91
Moreau, P., Harousseau, J., Wijdenes, J., Morineau, N., Milpied, N. J., & Bataille, R. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02093.x · Cited by 89
Voorhees, P. M., Chen, Q., Small, G. W., Kuhn, D. J., Hunsucker, S. A., Nemeth, J. A., & Orlowski, R. Z. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07647.x · Cited by 89
Leslie, K., Gao, S. P., Berishaj, M., Podsypanina, K., Ho, H. H., Ivashkiv, L. B., & Bromberg, J. (2010) · Breast Cancer Research · doi:10.1186/bcr2725 · Cited by 89
Pu, Y., Hour, T., Chuang, S., Cheng, A., Lai, M., & Kuo, M. (2004) · The Prostate · doi:10.1002/pros.20057 · Cited by 88
Borsellino, N., Bonavida, B., Ciliberto, G., Toniatti, C., Travali, S., & D’Alessandro, N. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990101)85:1<134::aid-cncr19>3.0.co;2-c · Cited by 84
New therapeutic strategies for treatment of inflammatory bowel disease
Atreya, R. N., & Neurath, M. F. (2008) · Mucosal Immunology · doi:10.1038/mi.2008.7 · Cited by 84
Shinriki, S., Jono, H., Ueda, M., Ota, K., Ota, T., Sueyoshi, T., Oike, Y., Ibusuki, M., Hiraki, A., Nakayama, H., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2935 · Cited by 84
Hunsucker, S. A., Magarotto, V., Kuhn, D. J., Kornblau, S. M., Wang, M. L., Weber, D. M., Thomas, S. K., Shah, J. J., Voorhees, P. M., Xie, H., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08533.x · Cited by 82
Soluble interleukin‐6 receptor (sIL‐6R), a new prognostic factor in multiple myeloma
Kyrtsonis, M., Dedoussis, G. V., Zervas, C., Perifanis, V., Baxevanis, C. N., Stamatelou, M., & Maniatis, A. G. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.4721018.x · Cited by 79
Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis.
Benedetti, F. D., Pignatti, P., Gerloni, V., Massa, M., Sartirana, P., Caporali, R. F., Montecucco, C., Corti, A., Fantini, F., & Martini, A. (1997) · PubMed · Cited by 79
Interleukin-6: A comprehensive review
Lotz, M. (1995) · Cancer treatment and research · doi:10.1007/978-1-4613-1241-3_8 · Cited by 74
Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma–associated herpesvirus
Aoki, Y., Narazaki, M., Kishimoto, T., & Tosato, G. (2001) · Blood · doi:10.1182/blood.v98.10.3042 · Cited by 74
Hudes, G., Tagawa, S., Whang, Y., Qi, M., Qin, X., Puchalski, T., Reddy, M., Cornfeld, M., & Eisenberger, M. (2013) · Investigational new drugs · doi:10.1007/s10637-012-9857-z · Cited by 71
Alten, R., & Maleitzke, T. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.771986 · Cited by 71
Ogata, A., & Tanaka, T. (2012) · International Journal of Rheumatology · doi:10.1155/2012/946048 · Cited by 69
Solary, É., Guiguet, M., Zeller, V., Casasnovas, O., Caillot, D., Chavanet, P., Guy, H., & Mack, G. (1992) · American Journal of Hematology · doi:10.1002/ajh.2830390303 · Cited by 68
Nanki, T., Onoue, I., Nagasaka, K., Takayasu, A., Ebisawa, M., Hosoya, T., Shirai, T., Sugihara, T., Hirata, S., Kubota, T., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202768 · Cited by 68
Iacopetta, B. M., Grieu, F., & Joseph, D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601545 · Cited by 67
Hönemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., Dörken, B., & Bargou, R. (2001) · International Journal of Cancer · doi:10.1002/ijc.1388 · Cited by 65
Finotto, S., Eigenbrod, T., Karwot, R., Boross, I., Doganci, A., Ito, H., Nishimoto, N., Yoshizaki, K., Kishimoto, T., Rose‐John, S., et al. (2007) · International Immunology · doi:10.1093/intimm/dxm037 · Cited by 65
Rossi, J. M., Fegueux, N., Lu, Z., Legouffe, É., Exbrayat, C., Bozonnat, M., Navarro, R., Lopez, E., Quittet, P., Daurès, J., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705138 · Cited by 60
Cited by
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 716
Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells
Jang, S., Kwon, E.-J., & Lee, J. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020905 · Cited by 612
Interleukin-6: A Masterplayer in the Cytokine Network
Uciechowski, P., & Dempke, W. C. M. (2020) · Oncology · doi:10.1159/000505099 · Cited by 465
Role of Interleukin-6 in Depressive Disorder
Ting, E. Y.-C., Yang, A. C., & Tsai, S.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062194 · Cited by 385
Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption
Kitaura, H., Marahleh, A., Ohori, F., Noguchi, T., Shen, W.-R., Qi, J., Nara, Y., Pramusita, A., Kinjo, R., & Mizoguchi, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145169 · Cited by 380
Metadata
- Authors
- Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 141
- Issue
- 2
- Pages
- 125-139
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1970433764
- Cited by
- 664
- References
- 239
- FWCI
- 18.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.